RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $24
RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $24
RBC Capital維持apellis pharmaceuticals板塊表現評級,將目標價下調至24美元
RBC Capital analyst Luca Issi maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Sector Perform and lowers the price target from $25 to $24.
RBC Capital分析師Luca Issi繼續維持Apellis Pharmaceuticals(納斯達克:APLS)的板塊表現評級,並將目標價從25美元降至24美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。